WELCOME TO MEDSHADOW. WE'VE UPDATED OUR LOOK!

Quick Hits: FDA Concerns Over Antibiotic & More

Contraceptives and Ovarian Cancer
Contraceptives and Ovarian Cancer

An FDA advisory committee has narrowly recommended approval of a new antibiotic to treat pneumonia. The committee voted 7-6 that the drug, solithromycin, is as effective as another antibiotic, Avelox (moxifloxacin). However, solithromycin has liver toxicity issues associated with it, according to an FDA review. In addition, agency staff had concerns about a relatively high number of infusion site-related reactions. Solithromycin is related to another antibiotic already on the market, Ketek (telithromycin), that has been linked with liver problems and is not frequently prescribed as a result. The FDA is slated to make a decision on whether or not to approve solithromycin by the end of December. Posted November 7, 2016. Via Reuters.

People who don’t get enough vitamin D may be at increased risk for bladder cancer. That conclusion was made by researchers based on a review of 7 studies conducted by scientists in the UK. Five out of the 7 studies linked low vitamin D levels to an increased risk of bladder cancer, according to a presentation at a medical conference by researchers at the University of Warwick. Prior research has linked vitamin D deficiency with cardiovascular disease, cognitive impairment, autoimmune diseases and cancer. The body naturally produces vitamin D through exposure to sunlight. Although more studies are needed, “our work suggests that low levels of vitamin D in the blood may prevent the cells within the bladder from stimulating an adequate response to abnormal cells,” the study’s lead author said in a news release. Posted November 8, 2016. Via University of Warwick.

The FDA has issued a new rule that limits a tactic used by pharmaceutical companies to delay generic drugs from coming to the market. Filing a “citizen petition” is intended to make the FDA aware of potential concerns with a drug’s risk or effectiveness and trigger a review. However, drug companies have filed such petitions in regard to generic drugs set to become available to delay competition. Brand-name firms filed 92% of the citizen petitions between 2011 and 2015, according to a recent review. More than 9 out of 10 of them were rejected by the FDA. Posted November 9, 2016. Via STAT.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
vitamin B tablets
Previous
B Vitamins
0
Would love your thoughts, please comment.x